KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non Operating Income: 2012-2025

Historic Other Non Operating Income for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$83.1 million.

  • Sarepta Therapeutics' Other Non Operating Income fell 682.24% to -$83.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$47.0 million, marking a year-over-year decrease of 284.80%. This contributed to the annual value of $42.7 million for FY2024, which is 111.02% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Other Non Operating Income stood at -$83.1 million, which was down 926.20% from $10.1 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Other Non Operating Income ranged from a high of $16.9 million in Q2 2023 and a low of -$387.3 million during Q1 2023.
  • Its 3-year average for Other Non Operating Income is -$52.9 million, with a median of $8.3 million in 2024.
  • In the last 5 years, Sarepta Therapeutics' Other Non Operating Income slumped by 39,849.36% in 2022 and then skyrocketed by 199.84% in 2023.
  • Sarepta Therapeutics' Other Non Operating Income (Quarterly) stood at -$60.6 million in 2021, then plummeted by 39,849.36% to -$125.4 million in 2022, then spiked by 90.17% to -$12.3 million in 2023, then skyrocketed by 195.77% to $10.1 million in 2024, then plummeted by 682.24% to -$83.1 million in 2025.
  • Its Other Non Operating Income stands at -$83.1 million for Q2 2025, versus $10.1 million for Q4 2024 and $11.8 million for Q3 2024.